The effect of homocysteine-lowering with B-vitamins on osteoporotic fractures in patients with cerebrovascular disease: substudy of VITATOPS, a randomised placebo-controlled trial

Table 4 **Mean homocysteine concentration at follow up* according to treatment group and fracture outcomes**

	With fracture mean (standard deviation)	Without fracture mean (standard deviation)	Difference, (95% confidence interval)	P-value (paired t-test)
Homocysteine (micromol/L
Placebo (n = 584)	15.7 (5.9) (n = 23)	14.2 (6.1) (n = 561)	−1.52 (−4.08,1.04)	0.2447
B-Vitamins (n =580)	11.7 (9.6) (n = 18)	10.5 (4.6) (n = 562)	−1.17 (−3.46,1.11)	0.3118

* The difference between baseline and follow-up Homocysteine levels were also compared between patients with and without facture. The differences are not significant, either (data not shown).
Note: Only a small subset of patients (14.3%) had homocysteine levels measured at final follow up.